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Abstract
Background: Several different classes of medications have been shown to be efficacious at preventing fractures in patients with
osteoporosis. No study has compared real world efficacy at preventing fractures between all currently approved medications.
Objectives: To directly compare the efficacy of all currently available osteoporosis medications by using a large population claims
database.
Methods: The Truven Health Analytics MarketScan® database from 2008 - 2012 was used to identify all patients who started a new
osteoporosis medication. Patients who experienced a fracture after at least 12 months of treatment were identified and risk factors
for fracture for all patients were recorded. Logistic regression was used to account for and quantify the contribution of risk factors,
and to make direct comparisons between different osteoporosis medications.
Results: A total of 51649 patients were included in the cohort, with an average age of 56 years. The overall incidence rate of frac-
ture was 1.55 per 100 person - years of treatment. Orally administered medications had the lowest fracture rates, led by raloxifene
and alendronate (1.24 and 1.54 respectively), while parenterally administered medications including teriparatide and zolerdonic
acid had the highest rates (3.90 and 1.98 respectively). No statistically significant differences found between oral or parenterally
administered bisphosphonate medications.
Conclusions: While patients taking orally administered drugs including bisphosphonates had less frequent incident fracture no
statistically significant differences were found between most drugs in head - to - head comparisons, even considering the route of
administration of bisphosphonates. These findings support previous evidence that minimal differences in efficacy exist between
different osteoporosis medications. This is the first study using a large database to compare all currently available osteoporosis
treatments and will hopefully be augmented by further study to provide more evidence to make clinical decisions on osteoporosis
medication use.
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1. Background
The consequences and complications of osteoporosis
impose a significant amount of morbidity, mortality and
economic burden on patients and societies worldwide. In
the United States, approximately one in five men and one
in two women over the age of 50 will have an osteoporosis
- related fracture (1), resulting in over two million fractures
and $19 billion in related costs each year (2).
Pharmacologic treatments for osteoporosis have been
shown in randomized controlled trials to reduce the in-
cidence of vertebrae fractures by approximately 50% and
non - vertebral fractures by about 30% (3-5). However, de-
spite good compliance the observed incidence of treat-
ment failure or inadequate clinical response has been re-
ported to be considerably higher than in randomized clin-
ical trials. Between 2-26% of compliant patients sustain
a fracture each year while being treated with osteoporo-
sis medications (6-8), and increased rates are found in pa-
tients who are less compliant (9-13).
Given that there is a relative paucity of evidence that
directly compares the effectiveness of different osteoporo-
sis medications, clinical decisions on choosing pharma-
cotherapy for patients often have an element of trial and
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error. Drugs are frequently selected based on reasons other
than efficacy, such as cost, insurance coverage, side effects,
route of administration and interactions with other drugs
or medical conditions. Studies that compare the efficacy
of osteoporosis drugs would be useful to lend a quantita-
tive, evidence - based element to making these decisions.
This study retrospectively used the MarketScan database to
quantify and compare real - world fracture rates among pa-
tients on each osteoporosis medication. We hypothesized
that patients on medications that are more frequently ad-
ministered orally would have the highest rate of fractures,
followed by self - injectable medications, and then intra-
venous, intramuscular and medications administered in
the hospital and office.
2. Methods
2.1. Data Source
The Truven Health Analytics MarketScan® Commercial
Claims and Encounters database from 2008 - 2012 was used
to identify patients for the study. The database contains
de - identified demographic information and paid claims
for inpatient and outpatient medical services and prescrip-
tions for commercial populations.
2.2. Patient Criteria
All patients who started a newly prescribed osteo-
porosis medication were identified. The medications in-
cluded in the study were alendronate, calcitonin, deno-
sumab, ibandronate, raloxifene, risedronate, teriparatide
and zolendronic acid. Only patients who had a 12 - month
period with no filled prescriptions for an osteoporosis
medication leading up to starting the new medication
were included in the study. Patients who sustained a frac-
ture within the first 12 months of starting a new osteoporo-
sis medication were excluded from the study to allow time
for therapeutic levels and results to be obtained.
2.3. Outcomes
This cohort was then divided into subgroups by each
medication, and the number of patients who sustained a
fracture at least 12 months after starting a new osteoporo-
sis medication was recorded, as well as demographic infor-
mation. Primary endpoint of fracture was used as this was
deemed as treatment failure in our intention to treat anal-
ysis. Further discussion of our choice of treatment failure
can be found in later sections of this report. Although per-
son years of treatment was used to quantify rate of frac-
ture, we counted each of these as a single incidence of
treatment failure, and did not include a time to event anal-
ysis.
Type and location of fracture were also identified by
ICD - 9 diagnosis code. In addition, information about risk
factors were collected for each group, including smoking,
alcohol use, rheumatoid arthritis, celiac disease, inflam-
matory bowel disease, type 1 diabetes, asthma, chronic ob-
structive pulmonary disease (COPD), osteoarthritis, use of
an oral glucocorticoid medication or a fall in the past 12
months. These factors were all identified in the database
by diagnosis using ICD-9 codes.
2.4. Statistical Analysis
Absolute numbers and proportion of individual sub
- cohorts, as well as unadjusted rates of fracture were
recorded and calculated. Logistic regression was also done
adjusting for all risk factors. Additionally, the logistic re-
gression models were repeated to compare all drugs head
to head with alendronate, which was the most widely pre-
scribed.
3. Results
3.1. Cohort Demographics and Outcomes
A total of 51649 patients met criteria to be included in
the cohort. The average age of these patients was 56.0 years
with a range from 50 - 63, and the majority was female,
with only 3208 males included in the cohort. The average
follow up for fracture surveillance was 732 days, approxi-
mately 2 years. This means that on average patients were
followed for 4 years: one year with no osteoporosis drug
use, one year taking a new drug to allow for efficacy to be
built up, and two years of fracture surveillance. There were
1610 patients who experienced a fracture, which amounted
to 3.1% of patients, and a rate of 1.55 fractures per 100 per-
son years of treatment. The distribution of patients by each
drug is listed in Table 1, along with the composition by
drug group of risk factors for fracture. Absolute fracture
rates for patients by each drug are listed in Table 2, and
by type of fracture in Table 3. Absolute fracture rates were
lowest for raloxifene and alendronate, and higher for less
commonly used, parenterally administered drugs includ-
ing zoledronic acid and teriparatide. The majority of frac-
tures by location that were capture by ICD - 9 codes were
wrist fractures, although almost half of the fractures were
not coded as a hip, wrist or vertebral fracture.
Patients taking denosumab were originally included
in the study but only 9 such patients met inclusion crite-
ria. Given the relatively small number, they were excluded
from the analysis.
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Table 1. Demographic Information and Risk Factors for Patients Taking each Osteoporosis Medicationa
Medication Alendronate Calcitonin Ibandronate Raloxifene Risedronate Teriparatide Zoledronic Acid Total
Total number of
patients
26395 1074 9956 4753 8815 524 132 51649
Male patients 2035 (7.7) 139 (13.0) 336 (3.4) 8 (0.17) 501 (5.7) 74 (14.1) 12 (9.1) 3208 (6.2)
Average age 56.8 57.1 56.6 56.7 56.5 56.9 56.9 56.0
Smoking 1759 (6.7) 78 (7.3) 585 (5.9) 187 (3.9) 466 (5.3) 46 (8.8) 6 (4.6) 5543 (10.7)
Alcohol abuse 177 (0.67) 8 (0.74) 63 (0.62) 17 (0.36) 35 (0.40) 6 (1.15) 1 (0.76) 580 (1.1)
Rheumatoid arthritis 1287 (4.9) 77 (7.2) 435 (4.4) 159 (3.4) 468 (5.3) 44 (8.4) 12 (9.1) 3947 (7.6)
Celiac disease 183 (0.69) 14 (1.3) 54 (0.54) 23 (0.48) 64 (0.73) 5 (0.95) 1 (0.76) 132 (0.3)
Inflammatory bowel
disease
1562 (5.9) 96 (8.9) 626 (6.3) 282 (5.9) 577 (6.6) 41 (7.8) 11 (8.3) 6393 (12.4)
Type I diabetes 625 (2.4) 34 (3.2) 181 (1.8) 77 (1.6) 200 (2.27) 10 (1.9) 5 (3.8) 2086 (4.0)
Type II Diabetes 8657 (32.8) 347 (32.3) 2768 (27.6) 1359 (28.6) 2777 (31.5) 162 (30.9) 44 (33.2) 16114 (31.2)
Use of oral
glucocorticoid drug
14867 (56.3) 709 (66.0) 5947 (59.7) 2660 (56.0) 5174 (58.7) 325 (62.0) 90 (68.2) 29772 (57.6)
Asthma, COPD, chronic
bronchitis, emphysema
5433 (20.6) 309 (28.8) 2028 (20.4) 891 (18.8) 1808 (20.5) 151 (28.8) 35 (26.5) 10655 (20.6)




7092 (26.9) 362 (33.7) 2796 (28.1) 1269 (26.7) 2329 (26.4) 198 (37.8) 47 (35.6) 14093 (27.3)
aAll values listed are number of patients with percent in brackets, except for age, which is expressed in years.
Table 2. Fracture Rate and Follow - up Period for Patients by each Osteoporosis Medicationa
Medication Alendronate Calcitonin Ibandronate Raloxifene Risedronate Teriparatide Zoledronic Acid Total
Total number of patients 26395 1074 9956 4753 8815 524 132 51649
Fractures 804 37 325 119 280 40 5 1610
Patients with fracture(s) (%) 3.05 3.45 3.26 2.50 3.18 7.63 3.79 3.12
Average follow-up (days) 724 717 741 735 751 714 697 732
Fracture rate per 100 person
years
1.54 1.75 1.61 1.24 1.54 3.9 1.98 1.55
aNo statistically significant differences were found in fracture rates aside from the rate for teriparatide being higher than all other ones. A more detailed and controlled
head - to - head analysis can be seen in Table 5.
Table 3. Number of Fractures in Different Sites by each Osteoporosis Medication
Medication Alendronate Calcitonin Ibandronate Raloxifene Risedronate Teriparatide Zoledronic Acid Total
Total number of patients 26395 1074 9956 4753 8815 524 132 51649
Hip fractures 87 5 31 13 26 6 0 168
Wrist fractures 273 4 103 34 99 3 2 518
Vertebrae fractures 89 8 45 19 34 2 0 197
Other fractures 355 20 146 53 121 29 3 727
Total Fractures 804 37 325 119 280 40 5 1,610
3.2. Logistic Regression Analysis
Logistic regression analysis yielded a controlled contri-
bution towards fractures for different risk factors to frac-
tures, as seen in Table 4. Most risk factors had statisti-
cally significant odds ratios greater than 1, indicating an
increased risk of fracture. Experiencing a fall in the 12
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months prior to starting an osteoporosis medication was
by far the most significant risk factor for experiencing a
fracture while being treated for osteoporosis in our cohort.
In descending order of magnitude of risk, having a prior
fall was followed by carrying a diagnosis of diabetes, os-
teoarthritis, alcohol abuse, and being a smoker. Other risk
factors that appeared to contribute to fractures included
inflammatory bowel disease, use of an oral glucocorticoid,
asthma and COPD. Factors found not to have a statistically
significant correlation included rheumatoid arthritis and
celiac disease. Table 5 shows the results of the logistic re-
gressions directly comparing each drug to alendronate.
For this analysis, confounders that were adjusted for were
smoking, alcohol abuse, rheumatoid arthritis, inflamma-
tory bowel disease, celiac disease, type 1 diabetes, type 2 di-
abetes, use of oral glucocorticoid, asthmas, COPD, chronic
bronchitis, emphysema, fall in past 12 months, osteoarthri-
tis and degenerative joint disease. Except for raloxifene,
the odds ratios were above 1, indicating increased risk of
fracture relative to alendronate, but only teriparatide was
statistically significant (OR 2.347, 95% CI 1.676 - 3.286). Al-
though the odds ratio for raloxifene was less than 1, indi-
cating decreased risk of fracture, it was not statistically sig-
nificant.
4. Discussion
The results of the direct comparison of different osteo-
porosis medications were opposite of our hypothesis. No
statistically significant results were found based on route
of administration of bisphosphonates, nor between ralox-
ifene and alendronate. Previous randomized trials and ret-
rospective studies have found no difference between al-
endronate and raloxifene, and other reviews and analyses
have concluded that minimal differences in efficacy exist
between different medication options (4, 14-16). The fact
that our study did not find statistically significant differ-
ences supports the results from these studies.
The only statistically significant difference in fracture
rate found by the study was between teriparatide and alen-
dronate. This likely represents confounding by indication,
since many patients taking teriparatide are prescribed it
due to an indication of previous fractures, or especially low
bone mineral density.
For almost all risk factors that were captured by avail-
able data, analysis showed statistically significant results
for them increasing the likelihood of experiencing a frac-
ture. The risk factors that were chosen in the study were
identified to mirror the validated FRAX model risk factors,
as much as was possible by using ICD - 9 codes. This analysis
showed experiencing a recent fall to be by far the most sig-
nificant risk factor. It is worth keeping in mind that most
studies evaluating risk factors looked at general popula-
tions, whereas our cohort included only patients currently
being treated for osteoporosis. Similar results have also
been found by studies that have identified risk factors for
treatment failure while on an osteoporosis medication (17,
18). Given the significant magnitude of risk found in this
study and other for patients who have had a recent fall or
fracture, it may be worth considering more intensive ther-
apy for these patients, including possibly using multiple
agents when initiating therapy.
The overall fracture rate for all patients included in the
study of 1.55 fractures per 100 person years of treatment
was at the lower end of the spectrum from previous stud-
ies. Although no studies have looked at such a wide range
of medications in a single study, rates of fractures per 100
person years have been reported between 0.8 and 9.5, with
most between 1 and 4 (6-8, 12, 15, 17, 19-26). These rates, as
well as data from randomized controlled trials have found
relative risk reduction of approximately 0.60 compared to
patients not taking osteoporosis medications (16). The re-
sults in our study therefore lie somewhere in between the
greater efficacy found in trials and the lesser efficacy that
has been noted in “real world” retrospective studies. A con-
trol group cohort was initially included in this study but re-
moved in favor of directly comparing medications to each
other.
Ultimately it is a difficult comparison to make between
this study and others since there are many parameters
that vary between them, including assessments of com-
pliance, duration of follow up and the medications that
were studies. In the present study, no assessment of com-
pliance was made, but inclusion criteria required a one -
year “wash out” period and a one - year period for efficacy
to be achieved. It is possible that we included patients who
had been on past long term (i.e. 5 or more years of oral bis-
phosphonates or 3 or more years of I.V. bisphosphonates),
and despite a “wash out” period of one year, that they were
still exhibiting an effect of the bisphosphonate given the
known long half - life of these drugs in bone. If they were
restarted on a bisphosphonate after a “drug holiday” it may
have accounted for the lower fracture rate in this group,
but there’s no way in knowing that from this database anal-
ysis.
Although many other studies have reported treatment
failure as 2 or more fractures, and most efficacy studies
control for patient compliance, we specifically did not
want to use these methods (6, 26). We felt that without
controlling for compliance we would capture a true, inten-
tion - to - treat efficacy for each drug, and have compliance
(or non - compliance) contribute to their overall efficacy
versus other medications. We also reported rates of a sin-
gle fracture since we felt that there is a more significant
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Table 4. Logistic Regression Results Indicating Risk Associated with Fracture While Being Treated for Osteoporosis, for each Factor
Fracture Risk Factor Wald Chi - Square P value Odds Ratio 95% Confidence Limits
Smoking 17.97 < 0.0001 1.457 1.224 1.733
Alcohol abuse 5.19 0.023 1.665 1.074 2.582
Rheumatoid arthritis 0.21 0.65 1.049 0.852 1.292
Celiac disease 0.51 0.48 1.227 0.700 2.148
Inflammatory bowel disease 4.35 0.037 1.215 1.012 1.460
Type I diabetes 19.89 < 0.0001 1.786 1.384 2.305
Use of oral glucocorticoid drug 6.31 0.012 1.149 1.031 1.280
Asthma, COPD, chronic bronchitis, emphysema 24.22 < 0.0001 1.337 1.191 1.501
Fall in past 12 months 438.44 < 0.0001 7.328 6.082 8.830
Osteoarthritis or degenerative joint disease 105.43 < 0.0001 1.731 1.559 1.922
Table 5. Logistic Regression Results for Head - to - head Drug Comparisons to Alendronate, with Regards to Fracture Incidencea
Drug Unadjusted Odds Ratio 95% Confidence Limit Odds Ratio 95% Confidence Limit
Calcitonin 1.14 0.81 1.59 1.03 0.73 1.44
Ibandronate 1.07 0.94 1.22 1.08 0.94 1.23
Raloxifene 0.82 0.67 0.99 0.87 0.72 1.07
Risendronate 1.04 0.91 1.20 1.07 0.93 1.23
Teriparatide 2.63 1.89 3.66 2.35 1.68 3.29
Zolendronic Acid 1.25 0.51 3.07 1.16 0.47 2.86
aVariables adjusted for: smoking, alcohol abuse, rheumatoid arthritis, inflammatory bowel disease, celiac disease, type 1 diabetes, type 2 diabetes, use of oral glucocor-
ticoid, asthma, COPD, chronic bronchitis, emphysema, fall in past 12 months, osteoarthritis and degenerative joint disease.
clinical difference between one and zero fractures, than be-
tween two and one fractures. For this reason we also gave a
significant amount of time for drug efficacy to be achieved
(12 months), before looking for patients who experienced
a fracture.
The weaknesses of this study include many of the well -
reported drawbacks of large claims database studies. Most
important among these, is that the data integrity is depen-
dent on the accuracy of the coding within the database and
that the sub - population within the database may or may
not represent the composition of other populations. The
lack of available bone mineral density data for all patients,
as mentioned above, is also a significant drawback of the
data set and study. Another difficulty in our study specifi-
cally was that limited use of newer drugs reduced the abil-
ity to identify statistically significant differences in com-
paring different medications. As previously mentioned,
more recently approved drugs account for a small propor-
tion of patients included in the study. The average age is
also a limitation of the study, as the patients captured in
this cohort were relatively young, with an average age of 56
and a range of 50 to 63 years of age. Although this does not
capture the age range of all patients who use osteoporosis
medications, this is still an age group where fracture pre-
vention and osteoporosis is a significant health problem,
as evidenced by the over 100000 patients captured in our
study. Finally, having a longer follow up period would also
be useful but was limited by the available data.
More studies comparing the efficacy of osteoporosis
medication would certainly serve to help direct evidence
- based decision making for health care providers. This
may be more achievable as use of new agents become more
prevalent. Consideration of drug efficacy in specific type of
patients and populations may also identify more specific
indications for individual drugs.
Overall, this study reaffirmed the efficacy of all osteo-
porosis medications in a large population database study.
Patients taking orally administered drugs including bis-
phosphonates had less frequent incident fracture, how-
ever statistically significant differences were not found in
head - to - head comparisons that accounted for risk fac-
tors. Ultimately this supports previous findings that mini-
mal differences in efficacy exist between the different med-
ications, and highlights the paucity of data available for
patients taking more recently approved medications. Pre-
viously established risk factors for fracture were also con-
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firmed to be risk factors for treatment failure across this
large cohort. This is the first study to use a large database
to compare all currently available osteoporosis treatments
and will hopefully be augmented by further study to pro-
vide more evidence to make clinical decisions on osteo-
porosis medication use.
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